Evid Invest
Who owns BRNSWhat BRNS owns — n/a

Who owns Barinthus Biotherapeutics plc.?

Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.

Institutional ownership of BRNS from SEC Form 13F filings across 15 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.

As of the 2026-06-30 reporting period, 15 institutions disclosed 9.2M shares of Barinthus Biotherapeutics plc. worth $7.8M — about 22.5% of shares outstanding; the largest disclosed holder is M&G PLC. Source: SEC Form 13F filings, parsed by EvidInvest.

15

13F holders

$7.8M

value, 2026 filers

22.5%

of shares outstanding (9.2M sh)

3

new positions (2026 filers)

Top institutional holders

ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of BRNS's shares outstanding

#ManagerSharesValue% of fund% of co.Δ shares QoQ
1M&G PLC5.2M$5.2M0.0%12.7%0.0%
2HSG Holding Ltd1.4M$937,5120.1%3.5%0.0%
3GLR Partners, LLC1.2M$820,6290.4%3%0.0%
4DC Funds, LP642,204$423,85533.8%1.6%0.0%
5Rangeley Capital, LLC185,136$122,1900.1%0.5%+16.1%
6Johns Hopkins University122,237$80,6760.0%0.3%0.0%
7MORGAN STANLEY108,843$71,8370.0%0.3%+4825.0%
8Baird Financial Group, Inc.105,961$69,9340.0%0.3%0.0%
9CITADEL ADVISORS LLC76,754$50,6580.0%0.2%-35.5%
10HighTower Advisors, LLC37,450$24,7170.0%0.1%0.0%
11RENAISSANCE TECHNOLOGIES LLC25,000$16,5000.0%0.1%-83.4%
12XTX Topco LtdNEW14,819$9,7810.0%0%new
13RHUMBLINE ADVISERS11,685$7,7120.0%0%0.0%
14TWO SIGMA SECURITIES, LLCNEW11,052$7,2940.0%0%new
15UBS Group AGNEW1,008$6650.0%0%new

Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.